等待开盘 11-17 09:30:00 美东时间
-0.071
-9.21%
11月14日,Compass Therapeutics(CMPX)收跌5.63%,报0.77美元,成交额119.96万美元,市值1.39亿美元。 行情数据 •...
11-14 07:52
今日重点评级关注:花旗:维持Faeth Therapeutics"买入"评级,目标价从55美元升至60美元;HC Wainwright & Co.:维持Ocular Therapeutix"买入"评级,目标价从25美元升至28美元
11-11 10:50
Wedbush analyst Robert Driscoll maintains Compass Therapeutics (NASDAQ:CMPX) with a Neutral and lowers the price target from $1 to $0.9.
11-10 23:35
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.13) by 15.38 percent. This is a 87.5 percent decrease over losses of $(0.08) per share from the same period last year.
11-09 21:10
Compass Therapeutics reported third-quarter 2026 financial results and provided updates on its pipeline. The company is advancing preparations for a BLA submission for tovecimig in patients with biliary tract cancer (BTC) and plans to engage further with the FDA. Data from the COMPANION-002 study of tovecimig were published in the Journal of Clinical Oncology and presented at the 2026 ESMO Congress. Cohort expansions for CTX-8371 (PD-1 x PD-L1 bi...
11-09 13:00
11月7日,Compass Therapeutics(CMPX)收涨10.84%,报0.76美元,成交额133.79万美元,市值1.37亿美元。 行情数据 •...
11-07 07:48
Compass Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, announced its participation in two investor events: the Guggenheim 3rd Annual Healthcare Innovation Conference on November 9, 2026, and the Stifel 2026 Healthcare Conference on November 11, 2026. Both events will feature webcasts available on the company's Events page. Management will be available for one-on-one meetings, and interested investors should contact the...
11-02 14:00
10月31日,Compass Therapeutics(CMPX)收涨4.01%,报0.79美元,成交额225.08万美元,市值1.42亿美元。 行情数据 •...
10-31 06:50
The COMPANION-002 study, published in the Journal of Clinical Oncology and presented at ESMO, demonstrated that tovecimig combined with paclitaxel significantly improved objective response rate (18.0% vs. 5.3%) and progression-free survival (4.7 vs. 2.6 months) in patients with previously treated advanced biliary tract cancer. The study also showed a 56% reduction in the risk of disease progression or death, durable responses (median DOR 4.9 mont...
10-24 08:15
10月24日,Compass Therapeutics(CMPX)收跌5.05%,报0.76美元,成交额162.53万美元,市值1.37亿美元。 行情数据 •...
10-24 06:55